|
"tan eng huat"的相關文件
顯示項目 1-6 / 6 (共1頁)
1
每頁顯示[10|25|50]項目
| 國立成功大學 |
2016-10 |
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
|
Mok, Tony Shu Kam; Geater, Sarayut Lucien; Su, Wu-Chou; Tan, Eng-Huat; Yang, James Chi-Hsin; Chang, Gee-Chen; Han, May; Komarnitsky, Philip; Payumo, Francis; Garrus, Jennifer E.; Close, Sandra; Park, Keunchil |
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC).
|
Yang, James Chih-Hsin; Ahn, Myung-Ju; Dickgreber, Nicolas J.; Halmos, Balazs; Hirsh, Vera; Hochmair, Maximilian J.; Levy, Benjamin Philip; De Marinis, Filippo; Mok, Tony; O'Byrne, Kenneth; Okamoto, Isamu; Schuler, Martin H.; Sebastian, Martin; Shah, Riyaz N. H.; Tan, Eng-Huat; Yamamoto, Nobuyuki; Marten, Angela; Massey, Dan; Wind, Sven; Carbone, David Paul; 楊志新 |
| 國立臺灣大學 |
2013 |
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
|
Lee, Chee Khoon; Brown, Chris; Gralla, Richard J.; Hirsh, Vera; Thongprasert, Sumitra; Tsai, Chun-Ming; Tan, Eng Huat; Ho, James Chung-Man; Chu, Da Tong; Zaatar, Adel; Osorio Sanchez, Jemela Anne; Vu, Vu Van; Au, Joseph Siu Kie; Inoue, Akira; Lee, Siow Ming; Gebski, Val; Yang, James Chih-Hsin; 楊志新 |
| 國立成功大學 |
2012-05 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin |
| 國立臺灣大學 |
2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
|
Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin; 楊志新 |
| 國立成功大學 |
2006-10 |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study
|
Chang, Alex; Parikh, Purvish; Thongprasert, Sumitra; Tan, Eng Huat; Perng, Reury- Perng; Ganzon, Domingo; Yang, Chih-Hsin; Tsao, Chao-Jung; Watkins, Claire; Botwood, Nick; Thatcher, Nick |
顯示項目 1-6 / 6 (共1頁)
1
每頁顯示[10|25|50]項目
|
